The Latest Breaking News from Moderna

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine despite the low immunization rate as developing nations struggle to allocate supplies. The African Union and Covax decided not to obtain more of the vaccine as developing nations struggle…

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna's shot, as developing nations struggle to allocate supplies. A spokesperson for Gavi, part of the COVAX alliance, confirmed the news. The discussions with Moderna are part of "regular decision-making…

For some parents of young children, the wait for COVID-19 vaccines has been long and agonizing.

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.

The FDA has approved a second round of the Moderna Inc (NASDAQ: 

Vaccine stocks jumped Tuesday after the FDA authorized another round of Covid booster shots for people age 50 and older.

The stock market gained as consumer confidence rose, peace talks resumed between Russia and Ukraine and vaccine stocks popped.

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.